What have we learned about systemic sclerosis from the EUSTAR database?

Area of Science:

• Rheumatology and immunology
• Rare disease research
• Clinical data science

Background:

• The European Scleroderma Trials and Research (EUSTAR) database is the world's largest international registry for systemic sclerosis (SSc).
• It contains longitudinal data from over 27,000 patients, collected over two decades of global collaboration.
• EUSTAR is crucial for understanding rare diseases, particularly with growing interest in real-world data and precision medicine.

Purpose of the Study:

• To synthesize key findings from the EUSTAR database.
• To highlight the registry's contribution to systemic sclerosis research and clinical practice.
• To outline future directions for leveraging this unique dataset.

Main Methods:

• Review and analysis of data from the EUSTAR international registry.
• Longitudinal data collection and patient enrollment exceeding 1,000 new patients annually.
• Application of innovative research methodologies, including emulated clinical trials and comparative effectiveness analyses.

Main Results:

• Clarification of systemic sclerosis phenotypes, disease trajectories, and predictors of organ involvement and mortality.
• Validation of outcome measures like the EUSTAR Activity Index.
• Identification of treatment pattern heterogeneity, refinement of classification criteria, and regional care disparities.

Conclusions:

• EUSTAR serves as a benchmark for rare disease collaborative research.
• Registry findings directly influence systemic sclerosis management guidelines and clinical practice.
• Future integration of digital tools and AI will enhance its role in clinical trial design and personalized medicine.